Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Valacyclovir for prevention of vertical CMV transmission
NCT02351102Phase 3Completed
- Sponsor
- Rabin Medical Center
- Start
- Nov 2015
- Primary completion
- Jul 2019
- Modality
- Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in congenital cytomegalovirus infection (cCMV) comparing Valacyclovir with Placebo (2 arms). Primary endpoint: Cytomegalovirus Polymerase Chain Reaction in amniotic fluid at 21 weeks. Started Nov 2015; status: completed.
02
Drugs
valaciclovir
03
Conditions
congenital cytomegalovirus infection (cCMV)
Beyond the preview
Go deeper on NCT02351102.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02351102.